Skip to main content
Equibles
XENE logo

XENE · Xenon Pharmaceuticals Inc.

Track XENE — free

Use XENE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about XENE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$62.35 -1.88 (-2.93%) At close · Aug 14
Market Cap
$6.04B
Shares
96.84M

Xenon Pharmaceuticals Inc. Earnings Call Transcripts

Every quarterly earnings call for Xenon Pharmaceuticals Inc. (XENE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼75.8% $536,000 −$31.16M '22 Q2 22-08-09 ▼98.4% $132,000 −$37.15M '22 Q3 22-11-08 ▼100% $ −$37.40M '22 Q4 23-03-01 · $ −$47.93M '24 Q1 24-05-09 · $ −$57.92M '24 Q2 24-08-08 · $ −$62.79M '24 Q3 24-11-12 · $ −$65.69M '24 Q4 25-02-27 · $7.50M −$65.05M '25 Q1 25-05-12 · $ −$84.71M '25 Q2 25-08-11 · $ −$90.90M '25 Q3 25-11-03 ▼100% $ −$102.30M '26 Q1 26-05-07 LATEST · $ −$110.74M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Xenon Pharmaceuticals Inc. Q2 FY2026 Earnings Call
Confident tone AZK NDA submission and launch readiness for focal seizures Pain pipeline (KV7 and Nav1.7) XTOL2 Phase 3 efficacy data and medical education
Revenue
$
Diluted EPS
$-1.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Xenon Pharmaceuticals Inc. Q1 FY2026 Earnings Call
Confident tone AZK Phase 3 Data & Regulatory Submission Commercial Launch Preparation Early-Stage Pain Pipeline
Revenue
$
▼ 100% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-22
Bloom Burton & Co. Healthcare Investor Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-03
Xenon Pharmaceuticals Inc. Q3 FY2025 Earnings Call
Confident tone Azetukalner differentiation and commercial profile X-TOLE2 Phase III readout in focal onset seizures Earlier-stage ion channel programs (Nav1.7, Kv7, Nav1.1)
Revenue
$
Diluted EPS
$-1.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Xenon Pharmaceuticals Inc. Q2 FY2025 Earnings Call
Confident tone Azetukalner Phase III X-TOLE2 in focal onset seizures Earlier-stage Nav1.1, Nav1.7 and Kv7 pipeline Major depressive disorder (MDD) Phase III program
Revenue
$
Diluted EPS
$-1.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Xenon Pharmaceuticals Inc. Q1 FY2025 Earnings Call
Positive tone Azetukalner Phase 3 epilepsy (X-TOLE2) Investigator-led MDD study results Azetukalner in MDD and bipolar depression
Revenue
$7.50M
Diluted EPS
$-0.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Xenon Pharmaceuticals Inc. Q4 FY2024 Earnings Call
Confident tone Phase 3 epilepsy readout / azetukalner MDD (major depressive disorder) program Bipolar depression program
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Xenon Pharmaceuticals Inc. Q3 FY2024 Earnings Call
Confident tone Azetukalner epilepsy program (X-TOLE) Nav1.7 pain program MDD program (X-NOVA)
Revenue
$
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Xenon Pharmaceuticals Inc. Q2 FY2024 Earnings Call
Confident tone Phase 3 azetukalner epilepsy program execution Nav1.7 sodium channel pain program X-ACKT primary generalized tonic-clonic seizure study
Revenue
$
Diluted EPS
$-0.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Xenon Pharmaceuticals Inc. Q1 FY2024 Earnings Call
Confident tone Azetukalner (XEN1101) INN naming milestone Phase III epilepsy program (X-TOLE2, X-TOLE3, X-ACKT) Kv7 pipeline and discovery portfolio
Revenue
$
Diluted EPS
$-0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Xenon Pharmaceuticals Inc. Q4 FY2023 Earnings Call
Confident tone XEN1101 Phase 3 Epilepsy Program (X-TOLE2/X-TOLE3/X-ACKT) MDD Development / X-NOVA Results FDA End-of-Phase 2 Meeting
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Xenon Pharmaceuticals Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Xenon Pharmaceuticals Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.72
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Xenon Pharmaceuticals Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Xenon Pharmaceuticals Inc. Q4 FY2022 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Xenon Pharmaceuticals Inc. Q3 FY2022 Earnings Call
Revenue
$132,000
▼ 98.4% YoY
Diluted EPS
$-0.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Xenon Pharmaceuticals Inc. Q2 FY2022 Earnings Call
Revenue
$536,000
▼ 75.8% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Xenon Pharmaceuticals Inc. Q1 FY2022 Earnings Call
Revenue
$8.77M
▲ 101.1% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Xenon Pharmaceuticals Inc. Q4 FY2021 Earnings Call
Revenue
$3.74M*
▼ 27.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Xenon Pharmaceuticals Inc. Q3 FY2021 Earnings Call
Revenue
$8.12M
▲ 24% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Xenon Pharmaceuticals Inc. Q2 FY2021 Earnings Call
Revenue
$2.22M
▼ 83.4% YoY
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Xenon Pharmaceuticals Inc. Q1 FY2021 Earnings Call
Revenue
$4.36M
▼ 38.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Xenon Pharmaceuticals Inc. Q4 FY2020 Earnings Call
Revenue
$5.15M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Xenon Pharmaceuticals Inc. Q3 FY2020 Earnings Call
Revenue
$6.55M
▲ 87.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Xenon Pharmaceuticals Inc. Q2 FY2020 Earnings Call
Revenue
$13.38M
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-21
Xenon Pharmaceuticals Inc. Q1 FY2020 Earnings Call
Revenue
$7.08M
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-09
Xenon Pharmaceuticals Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 earnings calls
Key facts CIK 1582313 CUSIP 98420N105 13F (30d) 307 filings 301 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)